{"disease": "Glioblastoma", "drug": "Acalabrutinib", "rationale_bullets": ["Acalabrutinib inhibits BTK, which is involved in B-cell receptor signaling and may impact tumor cell proliferation.", "Indirect associations via BRAF and CCND1 suggest potential relevance to glioblastoma biology.", "NF1 mutation/deletion is a key feature of the Mesenchymal subtype, which aligns with BTK's role in immune signaling pathways.", "GSEA pathway analysis highlights immune-related pathways, which are consistent with the Mesenchymal subtype's strong immune signatures.", "Phase II clinical trial (NCT04198922) is testing acalabrutinib for glioblastoma, indicating ongoing investigation."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Phase II clinical trial ongoing; potential relevance to glioblastoma biology."}}
{"disease": "Glioblastoma", "drug": "Alectinib", "rationale_bullets": ["Alectinib inhibits ALK, which is associated with glioblastoma, suggesting potential efficacy.", "Gene evidence shows involvement of NF1, a key gene in the Mesenchymal subtype, which is linked to Alectinib.", "GSEA pathways such as 'positive regulation of ERK1 and ERK2 cascade' and 'inflammatory response' are upregulated, aligning with Mesenchymal subtype features.", "Downregulation of 'positive regulation of protein kinase B signaling' and 'positive regulation of tumor necrosis factor production' supports anti-tumor activity.", "Mechanistic evidence indicates modulation of pathways related to cell survival, proliferation, and inflammation, relevant to glioblastoma biology.", "Combination of Alectinib with radiotherapy shows synergistic effects in glioblastoma cells, enhancing its therapeutic potential."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential efficacy due to ALK inhibition; combination with radiotherapy shows synergy."}}
{"disease": "Glioblastoma", "drug": "Alpelisib", "rationale_bullets": ["Alpelisib targets PIK3CA, which is implicated in glioblastoma through the PI3K/AKT pathway, a key driver in the Classical subtype.", "PTEN mutations, common in the Classical subtype, lead to PI3K/AKT pathway activation, which Alpelisib can inhibit.", "GSEA results show significant involvement of the PI3K/AKT/mTOR pathway (down, p<0.01), aligning with Alpelisib's mechanism of action.", "EGFR amplification, a hallmark of the Classical subtype, activates the PI3K/AKT pathway, which Alpelisib targets.", "Alpelisib has shown efficacy in other cancers with similar pathway activations, suggesting potential in glioblastoma.", "Indirect evidence links Alpelisib to glioblastoma through PIK3CA and CYP2C9, supporting its mechanistic relevance."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Targets PI3K/AKT pathway; potential in Classical subtype; combination with EGFR inhibitors suggested."}}
{"disease": "Glioblastoma", "drug": "Apitolisib", "rationale_bullets": ["Apitolisib inhibits PI3K and mTOR, which are critical pathways in glioblastoma cell proliferation and survival.", "EGFR amplification and PTEN mutation are key features of the Classical subtype, both of which are linked to the PI3K/AKT/mTOR pathway targeted by Apitolisib.", "Gene evidence shows frequent mutations in EGFR, PTEN, and PIK3CA in glioblastoma, supporting the drug's mechanism of action.", "GSEA pathway analysis highlights significant involvement of PI3K/AKT/mTOR signaling in glioblastoma, with low p-values and high overlap scores.", "Apitolisib's ability to induce apoptosis in glioblastoma cells aligns with the suppression of the PI3K/AKT/mTOR pathway, which is often dysregulated in the Classical subtype.", "The drug's mechanism directly targets pathways activated in the Classical subtype, suggesting potential efficacy in this subgroup."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential efficacy in Classical subtype; targets PI3K/AKT/mTOR pathway; requires further validation."}}
{"disease": "Glioblastoma", "drug": "Binimetinib", "rationale_bullets": ["Binimetinib inhibits MEK1/2, which is part of the RAS/RAF/MEK/ERK pathway, relevant to glioblastoma proliferation.", "Evidence suggests Binimetinib's efficacy in a BRAFV600E-mutant glioblastoma patient, indicating potential for broader application.", "NF1 mutation/deletion, a hallmark of the Mesenchymal subtype, leads to increased RAS pathway activity, which Binimetinib targets.", "GSEA pathway analysis shows significant involvement of the NF-κB pathway, which is activated in the Mesenchymal subtype.", "Key genes like NF1, EGFR, and PDGFRA are implicated in glioblastoma and are relevant to Binimetinib's mechanism of action.", "Binimetinib's indirect association with glioblastoma through IL1B suggests potential immune-modulatory effects, aligning with the Mesenchymal subtype's immune signatures."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Moderately high confidence; Mesenchymal subtype relevance; combination therapy suggested."}}
{"disease": "Glioblastoma", "drug": "Buparlisib", "rationale_bullets": ["Buparlisib inhibits pan-PI3K, which is relevant for glioblastoma due to frequent PTEN mutations leading to PI3K/AKT pathway activation.", "EGFR amplification is common in the Classical subtype, and Buparlisib's inhibition of PI3K can counteract EGFR-driven proliferation.", "GSEA pathway analysis shows significant downregulation of PI3K/AKT signaling, aligning with Buparlisib's mechanism and the Classical subtype's molecular features.", "PTEN mutations in glioblastoma result in loss of PI3K pathway inhibition, making Buparlisib a potentially effective therapeutic agent.", "Clinical evidence suggests Buparlisib may be more effective when combined with standard therapies like radiation and TMZ chemotherapy.", "Buparlisib's activity in recurrent glioblastoma, particularly PTEN-deficient cases, highlights its relevance to the Classical subtype."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Buparlisib inhibits pan-PI3K; relevant for glioblastoma due to PTEN mutations; potential combination with radiation and TMZ."}}
{"disease": "Glioblastoma", "drug": "Cobimetinib", "rationale_bullets": ["Cobimetinib inhibits MEK1/2, which is part of the RAS/RAF/MEK/ERK pathway frequently activated in glioblastoma, particularly in the Classical subtype.", "Direct disease-drug evidence links Cobimetinib to glioblastoma through multiple gene associations, including EGFR and PTEN, which are key markers of the Classical subtype.", "GSEA pathway analysis shows significant involvement of the MAPK signaling pathway (down, p<0.01), which is relevant to the drug's mechanism and the Classical subtype's biology.", "Key genes such as EGFR, PTEN, and CDK6 are implicated in glioblastoma and are targets or downstream effectors of Cobimetinib's action.", "The drug's mechanism of action aligns with the inhibition of cell proliferation and survival pathways that are hyperactivated in glioblastoma.", "Cobimetinib's FDA approval for other cancers (e.g., metastatic melanoma) supports its potential repurposing for glioblastoma, though specific glioblastoma trials are needed."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential repurposing for glioblastoma; needs specific trials."}}
{"disease": "Glioblastoma", "drug": "Copanlisib", "rationale_bullets": ["Copanlisib inhibits PI3Kα and PI3Kδ, which are involved in the PI3K/AKT pathway, a key pathway in glioblastoma biology.", "EGFR amplification and PTEN mutation are common in the Classical subtype of glioblastoma, both of which activate the PI3K/AKT pathway targeted by Copanlisib.", "GSEA pathway analysis shows significant involvement of PI3K/AKT signaling (down, p<0.01), which aligns with the drug's mechanism of action.", "PTEN loss leads to unchecked PI3K/AKT pathway activation, which Copanlisib can potentially counteract.", "EGFR signaling pathway activation is a hallmark of the Classical subtype, and Copanlisib's inhibition of downstream PI3K/AKT signaling could be beneficial.", "Copanlisib's previous FDA approval for follicular lymphoma indicates a known safety profile, though it was revoked due to lack of efficacy in further studies."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Copanlisib targets the PI3K/AKT pathway; previous FDA approval for follicular lymphoma."}}
{"disease": "Glioblastoma", "drug": "Dabrafenib", "rationale_bullets": ["Dabrafenib targets BRAF V600E, which is implicated in glioblastoma proliferation and survival.", "Clinical trial snippets suggest promising results for dabrafenib in glioblastoma, indicating potential efficacy.", "Gene-level evidence shows BRAF mutations lead to constitutive activation of the MAPK/ERK pathway, which dabrafenib inhibits.", "GSEA pathways such as 'regulation of ERK1 and ERK2 cascade' and 'positive regulation of MAPK cascade' are downregulated, aligning with dabrafenib's mechanism of action.", "Classical subtype features EGFR amplification and PTEN mutation, both of which are relevant to dabrafenib's target pathways.", "Pathways related to cell proliferation, migration, and cycle regulation are downregulated, supporting dabrafenib's potential to inhibit glioblastoma growth."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Dabrafenib targets BRAF V600E; promising clinical trial results; potential efficacy in glioblastoma."}}
{"disease": "Glioblastoma", "drug": "Duvelisib", "rationale_bullets": ["Duvelisib inhibits PI3Kδ and PI3Kγ, which are involved in the NF-κB pathway, relevant to the Mesenchymal subtype.", "Gene evidence shows NF1 mutation/deletion in Mesenchymal glioblastoma, which aligns with Duvelisib's mechanism targeting PI3K pathways.", "GSEA pathway analysis highlights NF-κB signaling (down, p<0.01) and immune response pathways, consistent with Mesenchymal subtype biology.", "Indirect associations via shared genes like CCND1, BRAF, and CDKN2A suggest potential relevance to glioblastoma.", "Snippet evidence mentions a fatal glioblastoma case post-Duvelisib treatment, indicating potential risk but also relevance.", "Duvelisib's immunomodulatory effects could be beneficial in targeting the strong immune signatures in Mesenchymal glioblastoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "negative_clinical_outcomes", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Moderate confidence; Mesenchymal subtype relevance; fatal glioblastoma case post-treatment."}}
{"disease": "Glioblastoma", "drug": "Encorafenib", "rationale_bullets": ["Encorafenib targets BRAF V600E, which is relevant in glioblastoma due to its role in the RAS/RAF/MEK pathway.", "Direct evidence links Encorafenib to glioblastoma through BRAF and CCND1, both associated with tumor proliferation.", "Classical subtype of glioblastoma often involves EGFR amplification and PTEN mutation, both of which interact with pathways targeted by Encorafenib.", "GSEA pathway analysis shows significant involvement of the RAS/RAF/MEK pathway, which is upregulated in glioblastoma and targeted by Encorafenib.", "Encorafenib has shown efficacy in a BRAFV600E-mutant glioblastoma patient, suggesting potential for broader application in this subtype.", "Mechanistic evidence supports Encorafenib's role in inhibiting cell proliferation and survival pathways active in glioblastoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Encorafenib targets BRAF V600E; potential efficacy in Classical subtype; combination therapy suggested."}}
{"disease": "Glioblastoma", "drug": "Ibrutinib", "rationale_bullets": ["Ibrutinib inhibits BTK, which is involved in NF-κB signaling, a pathway activated in the Mesenchymal subtype of Glioblastoma.", "Gene evidence shows NF1 mutation/deletion in Mesenchymal Glioblastoma, which aligns with Ibrutinib's mechanism of targeting NF-κB pathway.", "GSEA pathways such as 'negative regulation of cell motility' and 'negative regulation of cell migration' support Ibrutinib's potential to reduce glioblastoma invasion and metastasis.", "Downregulation of 'regulation of I-kappaB kinase/NF-kappaB signaling' pathway aligns with the Mesenchymal subtype's biology and Ibrutinib's mechanism.", "Ibrutinib's modulation of 'positive regulation of extrinsic apoptotic signaling pathway' supports its role in promoting apoptosis in glioblastoma cells.", "Indirect associations via shared genes like BRAF and CCND1 provide additional support for Ibrutinib's repurposing potential in Glioblastoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Moderately high confidence; Mesenchymal subtype focus; NF-κB pathway inhibition."}}
{"disease": "Glioblastoma", "drug": "Trametinib", "rationale_bullets": ["Trametinib inhibits MEK1/2, which is part of the RAS/RAF/MEK/ERK pathway frequently activated in glioblastoma, particularly in the Classical subtype with EGFR amplification.", "Gene evidence shows EGFR amplification and PTEN mutation in glioblastoma, both of which are relevant to the Classical subtype and can be targeted by MEK inhibition.", "GSEA indicates upregulation of the MAPK signaling pathway, which is directly targeted by Trametinib, suggesting effective pathway modulation.", "Downregulation of the NF-kappa B signaling pathway and cytokine-cytokine receptor interaction pathways may reduce inflammation and immune evasion, relevant to glioblastoma progression.", "Pathways related to cell proliferation and extracellular matrix organization are modulated, which are critical for tumor growth and invasion in glioblastoma.", "Interim clinical trial results and case series suggest potential clinical benefit of Trametinib in glioblastoma, supporting its repurposing potential."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential clinical benefit; targets relevant pathways in glioblastoma."}}
{"disease": "glioblastoma", "drug": "4'-epi-doxorubicin", "rationale_bullets": ["4epidoxorubicin shows indirect associations with glioblastoma through ALK and SOD2, which are relevant in mesenchymal GBM.", "Gene evidence indicates 4epidoxorubicin downregulates NOTCH2 and FOSL2, both implicated in mesenchymal GBM pathways.", "4epidoxorubicin upregulates AKT1 and AKT3, which are part of the PI3K/AKT pathway, a key pathway in mesenchymal GBM.", "GSEA results highlight pathways such as 'PI3K/AKT signaling' and 'NF-κB signaling', which are relevant to mesenchymal GBM.", "The drug's mechanism of action includes targeting IDH1 and MDM4, which are involved in glioblastoma pathogenesis.", "4epidoxorubicin's downregulation of BHLHE40 and MYC suggests potential therapeutic effects in glioblastoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Moderate confidence; moderately high risk; indirect associations with glioblastoma."}}
{"disease": "glioblastoma", "drug": "5-aminolevulinic acid", "rationale_bullets": ["5aminolevulinicacid targets ALAD, which is associated with key genes implicated in glioblastoma, such as NDRG1 and SOD2.", "Indirect associations via PIK3CA suggest potential relevance to glioblastoma, particularly through pathways involving cell growth and survival.", "Gene evidence indicates involvement in radioresistance (HEY1) and immune cell dynamics (S100B), aligning with mesenchymal GBM features.", "GSEA pathway results highlight inflammatory and immune-related pathways, which are characteristic of mesenchymal GBM.", "The drug's impact on MET expression supports its relevance to mesenchymal GBM, known for high MET expression.", "Pathway analysis suggests modulation of apoptosis and cell migration, relevant to mesenchymal GBM's aggressive nature."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential relevance to mesenchymal GBM; targets ALAD; impacts MET expression."}}
{"disease": "glioblastoma", "drug": "5-aza-2'-deoxycytidine", "rationale_bullets": ["5aza2deoxycytidine targets DNMT1, which is involved in epigenetic regulation and is relevant to glioblastoma biology.", "The drug shows potential in downregulating key genes like KRAS and BMI1, which are implicated in glioblastoma progression.", "GSEA pathway analysis highlights significant involvement in inflammatory and immune-related pathways, aligning with mesenchymal GBM features.", "The drug's impact on STAT3 and TNFSF10 suggests modulation of inflammatory and survival pathways, relevant to mesenchymal GBM.", "Indirect evidence links 5aza2deoxycytidine to glioblastoma through TNFSF10, a gene associated with inflammatory responses.", "The drug's mechanism of action and gene-level evidence suggest potential efficacy in targeting mesenchymal GBM, characterized by high immune infiltration and inflammatory signatures."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vitro_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential efficacy in mesenchymal GBM; targets DNMT1; impacts inflammatory pathways."}}
{"disease": "glioblastoma", "drug": "5-azacytidine", "rationale_bullets": ["5azacytidine targets DNMT1, which is linked to key genes implicated in glioblastoma, including TP53, EGFR, and NOTCH1.", "Indirect associations via TNFSF10 and IDH1 suggest potential relevance to glioblastoma biology.", "GSEA pathway analysis highlights significant involvement in inflammatory and immune-related pathways, which align with mesenchymal GBM features.", "Key genes such as PIM1, BRD2, and ITGB2 are involved in mesenchymal transition and immune regulation, supporting the mesenchymal subtype.", "5azacytidine's mechanism of action includes epigenetic modulation, which may impact glioblastoma stem cell behavior and therapy resistance.", "Experimental data from LINCS shows downregulation of genes like hes1 and mapkapk3, which are relevant to glioblastoma proliferation and survival."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "FDA approved for other indications; moderately high risk level; mesenchymal subtype focus."}}
{"disease": "glioblastoma", "drug": "5-fluorouracil", "rationale_bullets": ["5fluorouracil downregulates IDH1 expression, which is relevant for secondary glioblastomas progressing to GBM, aligning with proneural subtype biology.", "DUSP6 modulation by 5fluorouracil affects epithelial-to-mesenchymal transition and radiosensitivity, supporting its role in mesenchymal GBM.", "Upregulation of CXCL8 by 5fluorouracil suggests a mechanism for maintaining mesenchymal states and promoting chemoradiation resistance, aligning with mesenchymal GBM features.", "5fluorouracil affects TGFBR2 expression, influencing tumor invasion and proliferation, which is relevant for mesenchymal GBM's inflammatory signatures.", "NDRG1 inhibition by 5fluorouracil supports its tumor suppressor role, potentially beneficial across GBM subtypes but particularly mesenchymal due to its aggressive nature.", "GSEA pathway analysis highlights NF-kappaB activation and inflammatory pathways, which are upregulated and align with mesenchymal GBM biology."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential for mesenchymal GBM; combination therapy suggested."}}
{"disease": "glioblastoma", "drug": "Atezolizumab", "rationale_bullets": ["Atezolizumab targets PD-L1 (CD274), enhancing immune response against glioblastoma cells, which is relevant given the immune signatures in the Mesenchymal subtype.", "KG evidence links Atezolizumab to glioblastoma through genes like CCND1, HRAS, and MTOR, which are involved in pathways activated in glioblastoma.", "Gene-level evidence shows frequent mutations in NF1 and high expression of immune-related genes like CHI3L1 and MET in the Mesenchymal subtype, aligning with Atezolizumab's mechanism.", "GSEA pathway analysis highlights immune-related pathways such as NF-κB activation, which is upregulated in the Mesenchymal subtype and targeted by Atezolizumab.", "Clinical trials indicate the efficacy of Atezolizumab in combination with radiation and temozolomide in glioblastoma, supporting its potential use in this context.", "Indirect associations via shared genes like STAT3 and VEGFA, which are involved in immune evasion and angiogenesis, further support the rationale for Atezolizumab in glioblastoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential for use in glioblastoma; immune-related adverse events possible."}}
{"disease": "glioblastoma", "drug": "Axitinib", "rationale_bullets": ["Axitinib inhibits VEGFR, reducing angiogenesis, which is crucial in glioblastoma progression.", "Gene evidence shows Axitinib targets key genes like VEGFA, HIF1A, and STAT3, which are involved in glioblastoma biology.", "GSEA highlights downregulation of NF-kappa B signaling and Chemokine signaling pathways, which are critical in the Mesenchymal subtype.", "Mesenchymal subtype is characterized by NF1 mutation and strong immune signatures, aligning with Axitinib's modulation of immune effector processes.", "Axitinib's inhibition of pathways like TNF signaling and Proteoglycans in cancer suggests potential efficacy in reducing tumor growth and survival.", "Indirect associations via shared genes like TNFSF10 and NDRG1 support Axitinib's relevance in glioblastoma treatment."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Axitinib inhibits VEGFR; targets key genes in glioblastoma; potential efficacy in Mesenchymal subtype."}}
{"disease": "glioblastoma", "drug": "Belinostat", "rationale_bullets": ["Belinostat inhibits HDAC, leading to apoptosis and reduced proliferation in glioblastoma cells, aligning with the need to target cell cycle and survival pathways in glioblastoma.", "Gene evidence shows Belinostat downregulates key glioblastoma genes such as EGFR, TP53, and IDH1, which are critical in the Proneural subtype.", "GSEA pathway analysis highlights significant pathways like 'Cell Cycle' (down, p<0.01) and 'Apoptosis' (up, p<0.01), which are relevant to glioblastoma biology.", "Belinostat's modulation of IDH1 and TP53 aligns with the Proneural subtype's genetic markers, suggesting a targeted therapeutic potential.", "The drug's impact on the PDGF signaling pathway, a hallmark of the Proneural subtype, further supports its relevance.", "Clinical snippets indicate ongoing trials and preliminary positive outcomes in glioblastoma patients, reinforcing the potential clinical applicability."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Belinostat shows promise in glioblastoma; ongoing trials indicate potential benefits."}}
{"disease": "glioblastoma", "drug": "Bevacizumab", "rationale_bullets": ["Bevacizumab inhibits VEGF, reducing angiogenesis, which is crucial in glioblastoma progression.", "Mesenchymal GBM is characterized by high expression of CHI3L1 and MET, both of which are linked to Bevacizumab's mechanism.", "Gene evidence shows Bevacizumab's relevance to key mesenchymal GBM genes like NF1, PTEN, and CHI3L1.", "GSEA pathway analysis highlights significant pathways such as angiogenesis and immune response, which align with mesenchymal GBM features.", "Bevacizumab's anti-angiogenic effects are supported by its interaction with VEGFA, a key driver in glioblastoma.", "Clinical snippets indicate Bevacizumab's efficacy in recurrent glioblastoma, supporting its use in mesenchymal subtype."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_glioblastoma", "Q2_Research_status": "FDA_approved_for_glioblastoma", "Q3_interest": "Have_already_tested (or FDA-approved)", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "FDA approved for glioblastoma; High confidence level; Moderate risk level."}}
{"disease": "glioblastoma", "drug": "Bortezomib", "rationale_bullets": ["Bortezomib inhibits the proteasome, leading to apoptosis in glioblastoma cells, with evidence of effectiveness in resistant glioblastoma models.", "Gene-level evidence shows Bortezomib affects key glioblastoma genes such as EGFR, PTEN, TP53, and PDGFRA, which are relevant to glioblastoma biology.", "Bortezomib downregulates MGMT, potentially improving response to alkylating agents in glioblastoma treatment.", "GSEA pathway analysis highlights significant involvement in NF-κB signaling (down, p<0.01), which is crucial in the Mesenchymal subtype.", "Bortezomib's interaction with NF1 and CHI3L1, key markers of the Mesenchymal subtype, supports its potential efficacy in this subtype.", "Bortezomib's modulation of STAT3 and VEGFA, both implicated in glioblastoma progression and angiogenesis, aligns with its proposed mechanism of action."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential efficacy in Mesenchymal subtype; combination therapy suggested."}}
{"disease": "glioblastoma", "drug": "Brigatinib", "rationale_bullets": ["Brigatinib targets ALK, EGFR, and MET, which are associated with glioblastoma, particularly in the Classical subtype characterized by EGFR amplification/mutation.", "EGFR is frequently amplified and mutated in Classical GBM, promoting cell proliferation and survival via PI3K/AKT and RAS/RAF/MEK/ERK pathways, which Brigatinib can inhibit.", "CDK4 and CDK6, involved in cell cycle regulation, are amplified in glioblastoma and interact with pathways targeted by Brigatinib, suggesting potential efficacy.", "GSEA pathway analysis shows significant involvement of PI3K/AKT/mTOR signaling (downregulated), aligning with Brigatinib's mechanism of action and the molecular features of Classical GBM.", "MTOR and AKT1, key components of the PI3K/AKT pathway, are frequently activated in glioblastoma, and Brigatinib's inhibition of these pathways supports its potential use in this context.", "ALK overexpression and gene fusions in glioblastoma provide a direct target for Brigatinib, reinforcing its potential efficacy in this disease."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Targets ALK, EGFR, and MET; potential efficacy in Classical GBM subtype."}}
{"disease": "glioblastoma", "drug": "Cabozantinib", "rationale_bullets": ["Cabozantinib targets MET, which is highly expressed in mesenchymal GBM, suggesting potential efficacy in this subtype.", "Gene evidence shows Cabozantinib affects key genes in mesenchymal GBM, including PTEN and NF1, which are frequently mutated in this subtype.", "GSEA pathways such as 'neutrophil degranulation' and 'positive regulation of wound healing' (upregulated) align with the inflammatory and immune features of mesenchymal GBM.", "Downregulation of pathways like 'regulation of apoptotic process' and 'Proteoglycans in cancer' may reduce tumor growth and invasion, relevant to mesenchymal GBM biology.", "Cabozantinib's inhibition of angiogenesis via VEGFA and MET pathways is crucial for targeting the highly vascularized mesenchymal GBM.", "Evidence from clinical trials and systematic reviews supports Cabozantinib's potential in treating solid tumors, including glioblastoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential efficacy in mesenchymal GBM; targets MET and PTEN pathways; requires careful monitoring for severe adverse events."}}
{"disease": "glioblastoma", "drug": "Carfilzomib", "rationale_bullets": ["Carfilzomib inhibits the proteasome, leading to apoptosis in glioblastoma cells, which aligns with the aggressive nature of the Mesenchymal subtype.", "Gene evidence shows Carfilzomib's interaction with NF-κB pathway genes (RELA, NFKBIA), which are crucial in the Mesenchymal subtype.", "GSEA pathway analysis highlights significant involvement in NF-κB signaling (down, p<0.01), supporting the drug's potential efficacy in Mesenchymal glioblastoma.", "Carfilzomib's effect on STAT3 and TNFSF10, both involved in immune regulation and apoptosis, aligns with the immune signatures of the Mesenchymal subtype.", "Indirect associations via shared genes (e.g., BRAF, CDKN2A) suggest potential therapeutic synergy in glioblastoma treatment.", "Proteasome addiction due to PTEN deficiency in glioblastoma provides a mechanistic basis for Carfilzomib's efficacy."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Proteasome inhibitor; potential synergy with NF-κB pathway modulation."}}
{"disease": "glioblastoma", "drug": "Carmustine", "rationale_bullets": ["Carmustine alkylates DNA and RNA, causing cytotoxicity in glioblastoma cells, which aligns with its known mechanism of action.", "Direct evidence links Carmustine to glioblastoma treatment, including its use in interstitial chemotherapy with wafers.", "Key genes such as EGFR, PTEN, and TP53, which are frequently altered in the Classical subtype of glioblastoma, are targeted by Carmustine.", "GSEA pathway analysis shows significant involvement of the PI3K/AKT and RAS/RAF/MEK/ERK pathways, which are critical in the Classical subtype.", "Carmustine's effect on MGMT promoter methylation status suggests enhanced efficacy in glioblastoma with this epigenetic feature.", "The drug's impact on VEGFA and HIF1A indicates potential to inhibit angiogenesis, a key process in glioblastoma progression."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": true, "Q8_supporting_evidence_pmids": [], "Q9_note": "Direct evidence links Carmustine to glioblastoma treatment; Carmustine alkylates DNA and RNA causing cytotoxicity."}}
{"disease": "glioblastoma", "drug": "Ceritinib", "rationale_bullets": ["Ceritinib inhibits ALK, which is implicated in glioblastoma through overexpression and gene fusions, suggesting potential efficacy in reducing tumor proliferation.", "Gene evidence shows Ceritinib affects STAT3, a key gene in mesenchymal GBM, promoting cell proliferation and survival.", "GSEA pathway analysis highlights the NF-kappa B signaling pathway (upregulated), which is crucial for inflammation and cancer progression, aligning with mesenchymal GBM features.", "Ceritinib's impact on cytokine-mediated signaling pathways (upregulated) suggests modulation of immune interactions, relevant to the high immune infiltration in mesenchymal GBM.", "Downregulation of the Ras signaling pathway by Ceritinib indicates potential inhibition of KRAS-driven tumor growth, relevant to glioblastoma biology.", "Ceritinib's suppression of VEGFA expression aligns with the regulation of angiogenesis pathway (upregulated), which is critical for tumor growth and survival in glioblastoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential efficacy in mesenchymal GBM; requires further in vitro and in vivo studies."}}
{"disease": "glioblastoma", "drug": "Cetuximab", "rationale_bullets": ["Cetuximab targets EGFR, which is frequently amplified and mutated in glioblastoma, particularly in the Classical subtype.", "Gene evidence shows that EGFR, PTEN, and TP53, key markers of the Classical subtype, are relevant to Cetuximab's mechanism of action.", "GSEA pathway analysis highlights the PI3K/AKT and RAS/RAF/MEK/ERK pathways, which are critical in glioblastoma and are influenced by EGFR inhibition.", "Cetuximab has shown potential in preclinical models of glioblastoma, including studies involving focused ultrasound and exosome-mediated delivery.", "Pathway evidence suggests that Cetuximab downregulates HIF1A and VEGFA, which are involved in glioblastoma angiogenesis and survival.", "The drug's mechanism aligns with the inhibition of EGFR signaling, a hallmark of the Classical glioblastoma subtype, suggesting potential efficacy."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Cetuximab targets EGFR; potential efficacy in Classical subtype; preclinical models show promise."}}
{"disease": "glioblastoma", "drug": "Crizotinib", "rationale_bullets": ["Crizotinib targets ALK and MET, both of which are associated with glioblastoma, particularly in the mesenchymal subtype.", "Mesenchymal GBM features high MET expression, which Crizotinib directly inhibits, suggesting potential efficacy.", "GSEA pathways such as MAPK signaling, HIF-1 signaling, and cellular response to HGF stimulus are upregulated in glioblastoma and are relevant to Crizotinib's mechanism of action.", "Crizotinib's inhibition of MET and ALK can impact key genes like NF1 and PTEN, which are frequently altered in mesenchymal GBM.", "Downregulation of pathways like cholesterol biosynthesis and sterol biosynthetic process by Crizotinib may impair glioblastoma cell proliferation and survival.", "Clinical evidence from trials suggests safety and efficacy of Crizotinib in combination with standard glioblastoma treatments, supporting its potential repurposing."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Targets MET and ALK; potential efficacy in mesenchymal GBM; combination therapy suggested."}}
{"disease": "glioblastoma", "drug": "Dasatinib", "rationale_bullets": ["Dasatinib inhibits Src family kinases, which are important in glioblastoma biology, particularly in the mesenchymal subtype characterized by NF1 loss/mutation and PTEN loss.", "Gene evidence shows Dasatinib targets multiple kinases interacting with key glioblastoma genes such as EGFR, PTEN, and PDGFRA, which are relevant to glioblastoma pathogenesis.", "GSEA pathway analysis indicates Dasatinib downregulates pathways involved in cell migration, angiogenesis, and cell proliferation, which are critical for glioblastoma progression.", "Upregulation of pathways like TGF-beta receptor signaling and chemokine response aligns with the inflammatory and immune signatures of mesenchymal GBM.", "Key genes such as NF1, PTEN, and MET, which are highly relevant to mesenchymal GBM, are targeted by Dasatinib, suggesting potential efficacy in this subtype.", "Clinical snippets and preclinical studies suggest Dasatinib's potential in enhancing therapeutic efficacy in glioblastoma, particularly in mesenchymal GBM with high immune infiltration and inflammatory signatures."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential efficacy in mesenchymal GBM; targets key genes like NF1 and PTEN."}}
{"disease": "glioblastoma", "drug": "Durvalumab", "rationale_bullets": ["Durvalumab inhibits PD-L1, enhancing immune response against glioblastoma cells, which is relevant for the Mesenchymal subtype characterized by strong immune signatures.", "Gene evidence shows Durvalumab's interaction with STAT3, a key gene in glioblastoma, particularly in the Mesenchymal subtype where STAT3 activation is prominent.", "GSEA pathway analysis highlights immune-related pathways such as 'Interferon Gamma Response' (up, p=0.001) and 'TNF Signaling' (up, p=0.002), which align with the immune activation seen in Mesenchymal glioblastoma.", "Durvalumab's mechanism involving CD274 (PD-L1) and its interaction with mTOR and STAT3 supports its potential efficacy in glioblastoma, particularly in subtypes with immune involvement.", "Clinical snippets indicate ongoing trials and studies exploring Durvalumab in glioblastoma, suggesting emerging evidence for its repurposing potential.", "Indirect associations via genes like CCND1, HRAS, and NCOR1, which are implicated in glioblastoma, further support the rationale for considering Durvalumab."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Moderately high confidence; relevant for Mesenchymal subtype; ongoing trials."}}
{"disease": "glioblastoma", "drug": "Entrectinib", "rationale_bullets": ["Entrectinib targets TRK, ROS1, and ALK, which are relevant in glioblastoma biology, particularly through pathways involving EGFR and PTEN.", "Knowledge graph evidence shows multiple associations between Entrectinib targets (NTRK1/2/3, JAK2) and glioblastoma-related genes (CTNNB1, PIK3R1, EGFR).", "Clinical snippets indicate successful treatment of glioblastoma cases with NTRK and ROS1 fusions using Entrectinib.", "GSEA pathway analysis highlights significant involvement of PI3K/AKT and MAPK pathways, which are critical in glioblastoma, particularly the Classical subtype.", "Gene-level evidence shows that Entrectinib's targets interact with key glioblastoma genes like EGFR, PTEN, and TP53, aligning with the Classical subtype's molecular features.", "Pathway analysis suggests that Entrectinib may modulate key signaling pathways (e.g., PI3K/AKT, MAPK) relevant to glioblastoma progression and treatment response."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Entrectinib targets relevant pathways in glioblastoma; positive clinical outcomes noted."}}
{"disease": "glioblastoma", "drug": "Erlotinib", "rationale_bullets": ["Erlotinib targets EGFR, which is frequently amplified and mutated in Classical GBM, aligning with the drug's mechanism of action.", "Gene evidence shows strong associations between EGFR, PTEN, and TP53 with glioblastoma, supporting the potential efficacy of erlotinib.", "GSEA pathways such as 'positive regulation of nucleic acid-templated transcription' and 'positive regulation of transcription, DNA-templated' are upregulated, indicating active transcriptional processes in glioblastoma that erlotinib may target.", "Downregulation of pathways like 'negative regulation of apoptotic process' and 'regulation of angiogenesis' suggests that erlotinib may enhance apoptosis and inhibit angiogenesis in glioblastoma cells.", "The presence of EGFR amplification/mutation and RTK/MAPK signaling activation in Classical GBM aligns with erlotinib's inhibition of EGFR, suggesting a subtype-specific therapeutic potential.", "Erlotinib's known efficacy in other cancers with EGFR mutations (e.g., NSCLC) provides a rationale for its repurposing in glioblastoma, particularly in the Classical subtype."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Targets EGFR; potential efficacy in Classical GBM; dermatologic toxicities noted."}}
{"disease": "glioblastoma", "drug": "Etoposide", "rationale_bullets": ["Etoposide inhibits topoisomerase II, causing DNA strand breaks in glioblastoma cells, which aligns with its anti-neoplastic mechanism.", "Etoposide decreases EGFR expression, which is frequently amplified in the Classical subtype of glioblastoma.", "PTEN and TP53, both frequently mutated in the Classical subtype, are affected by Etoposide, suggesting potential therapeutic relevance.", "GSEA pathway analysis shows significant involvement of DNA damage response and repair pathways, which are relevant to Etoposide's mechanism of action.", "Etoposide's interaction with key genes like EGFR, PTEN, and TP53 supports its potential efficacy in the Classical subtype of glioblastoma.", "Indirect evidence from gene-level associations and pathway analysis suggests a mechanistic link between Etoposide and glioblastoma biology."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential for severe myelosuppression; risk of secondary malignancies; combination therapy suggested."}}
{"disease": "glioblastoma", "drug": "Everolimus", "rationale_bullets": ["Everolimus inhibits mTOR, a key regulator in the PI3K/AKT/mTOR pathway, which is frequently dysregulated in glioblastoma.", "PTEN loss, common in Mesenchymal GBM, leads to hyperactivation of the PI3K/AKT/mTOR pathway, making mTOR inhibition by Everolimus potentially effective.", "NF1 loss/mutation, characteristic of Mesenchymal GBM, results in increased cell proliferation via the RAS pathway, which intersects with mTOR signaling.", "GSEA pathway analysis highlights significant downregulation of inflammatory and immune-related pathways, aligning with the high immune infiltration seen in Mesenchymal GBM.", "Everolimus shows efficacy in PTEN-deficient cancers, which is relevant given the frequent PTEN loss in Mesenchymal GBM.", "Everolimus modulates key genes like STAT3 and RELA, which are involved in inflammatory and survival pathways, crucial for Mesenchymal GBM biology."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential efficacy in PTEN-deficient and NF1-mutant GBM; requires further in vitro and in vivo studies."}}
{"disease": "glioblastoma", "drug": "Gefitinib", "rationale_bullets": ["Gefitinib targets EGFR, which is frequently amplified and mutated in Classical GBM, aligning with the drug's mechanism of action.", "Disease–drug evidence shows direct associations between gefitinib and glioblastoma, including synergistic effects with temozolomide.", "Gene-level evidence supports gefitinib's impact on key genes like EGFR, PTEN, and CDKN2A, which are crucial in Classical GBM.", "GSEA pathway analysis indicates gefitinib downregulates pathways involved in cell proliferation and survival, such as the Ras and Notch signaling pathways.", "Upregulated pathways like inflammatory response and chemokine signaling suggest gefitinib may modulate the tumor microenvironment.", "Gefitinib's inhibition of the ERK1/2 cascade and regulation of cell population proliferation aligns with the molecular features of Classical GBM."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Targets EGFR; synergistic with temozolomide; potential severe interstitial lung disease risk."}}
{"disease": "glioblastoma", "drug": "Imatinib", "rationale_bullets": ["Imatinib targets PDGFRA, which is often amplified and overexpressed in glioblastoma, particularly in the proneural subtype.", "Gene evidence shows Imatinib's interaction with key glioblastoma-associated genes such as PDGFRA, TP53, and IDH1, which are relevant to the proneural subtype.", "GSEA pathway analysis indicates downregulation of pathways related to cell proliferation and motility, aligning with Imatinib's mechanism as a tyrosine kinase inhibitor.", "Pathways such as 'positive regulation of cell population proliferation' and 'positive regulation of protein kinase activity' are downregulated, suggesting Imatinib's potential to inhibit glioblastoma growth.", "Upregulated pathways like 'cellular response to oxidative stress' and 'regulation of programmed cell death' indicate Imatinib's impact on tumor cell survival mechanisms.", "The evidence supports Imatinib's potential efficacy in the proneural subtype, which is characterized by PDGFRA amplification and IDH1 mutations."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vitro_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential efficacy in proneural subtype; combination therapy suggested."}}
{"disease": "glioblastoma", "drug": "Ipilimumab", "rationale_bullets": ["Ipilimumab targets CTLA-4, enhancing immune response, which is relevant for glioblastoma's immune evasion mechanisms.", "KG evidence links ipilimumab to glioblastoma through genes like SIK1, CDK6, PTK2, MTOR, PDGFRA, and PIK3R1, which are involved in glioblastoma pathogenesis.", "Gene-level evidence shows ipilimumab's indirect interactions with key glioblastoma genes such as EGFR, TP53, MGMT, VEGFA, and NOTCH1, supporting its potential efficacy.", "GSEA pathway analysis highlights immune-related pathways such as NF-κB activation, which aligns with the mesenchymal subtype's strong immune signatures.", "Mesenchymal subtype is characterized by NF1 mutation and high expression of immune-related genes like CHI3L1 and MET, which may respond well to immune checkpoint inhibitors like ipilimumab.", "Ipilimumab's mechanism of action and gene-level interactions suggest potential benefits in targeting the mesenchymal subtype's aggressive and immune-rich profile."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "FDA-approved for other indications; potential immune-related adverse events."}}
{"disease": "glioblastoma", "drug": "Ixazomib", "rationale_bullets": ["Ixazomib inhibits proteasome activity, leading to apoptosis in glioblastoma cells, which aligns with the aggressive nature of the Mesenchymal subtype.", "Gene evidence shows Ixazomib downregulates key genes like PDGFRA, VEGFA, and CDK4, which are crucial for glioblastoma proliferation and angiogenesis.", "GSEA pathways such as 'regulation of vascular endothelial growth factor signaling pathway' and 'regulation of cell migration' are upregulated, indicating potential inhibition of tumor growth and invasion.", "The Mesenchymal subtype is characterized by NF1 mutations and strong immune signatures, which align with Ixazomib's modulation of immune response pathways.", "Downregulation of pathways like 'neutrophil degranulation' and 'innate immune response' suggests Ixazomib may reduce tumor-associated inflammation, beneficial for the Mesenchymal subtype.", "Ixazomib's impact on the 'regulation of angiogenesis' pathway supports its potential to inhibit tumor vascularization, a critical process in glioblastoma progression."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Moderately high confidence; potential for reducing tumor-associated inflammation; requires further in vitro and in vivo studies."}}
{"disease": "glioblastoma", "drug": "Larotrectinib", "rationale_bullets": ["Larotrectinib targets NTRK fusions, which are present in some glioblastomas, particularly in the proneural subtype.", "Evidence from case reports and clinical snippets indicates efficacy in NTRK-rearranged glioblastoma.", "Gene-level evidence shows interactions with key glioblastoma genes such as EGFR, PDGFRA, and CDK4, which are relevant to the proneural subtype.", "GSEA pathway analysis highlights significant pathways like PI3K/AKT signaling and MAPK signaling, which are relevant to glioblastoma biology.", "Larotrectinib's mechanism of action involves inhibiting TRK, which can reduce proliferation in glioblastoma cells.", "Indirect associations via shared genes (e.g., CTNNB1, PIK3CA) support the potential therapeutic relevance of Larotrectinib in glioblastoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": true, "Q8_supporting_evidence_pmids": [], "Q9_note": "Targets NTRK fusions; efficacy in NTRK-rearranged glioblastoma; potential neurotoxicity."}}
{"disease": "glioblastoma", "drug": "Lenvatinib", "rationale_bullets": ["Lenvatinib inhibits multiple receptor tyrosine kinases, including PDGFRA, which is frequently amplified in glioblastoma, suggesting potential efficacy.", "Gene evidence shows strong links between Lenvatinib targets (PDGFRA, FGFR1, FGFR2, FGFR3, FGFR4) and glioblastoma, particularly in pathways promoting cell proliferation and survival.", "Mesenchymal GBM subtype is characterized by NF1 loss/mutation, frequent PTEN loss, and high expression of CHI3L1 and MET, aligning with Lenvatinib's inhibition of MET and involvement in inflammatory signatures.", "GSEA pathway analysis highlights significant pathways such as 'PI3K-AKT signaling pathway' (down, p=0.001) and 'MAPK signaling pathway' (down, p=0.002), which are crucial in glioblastoma biology and targeted by Lenvatinib.", "Lenvatinib's mechanism of action includes reducing angiogenesis and proliferation, which is relevant for the highly vascularized and proliferative nature of glioblastoma.", "Clinical snippets indicate ongoing investigations and trials for Lenvatinib in glioblastoma, supporting its potential repurposing."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential efficacy in mesenchymal GBM; ongoing investigations and trials."}}
{"disease": "glioblastoma", "drug": "Lomustine", "rationale_bullets": ["Lomustine alkylates DNA, leading to apoptosis in glioblastoma cells, which aligns with its mechanism of action in brain cancer.", "Direct associations with glioblastoma-related genes such as CDKN2A, MGMT, and VEGFA support its potential efficacy in glioblastoma treatment.", "GSEA pathway analysis highlights significant involvement in DNA damage response and cell cycle regulation pathways, which are critical in glioblastoma biology.", "Classical GBM subtype is characterized by CDKN2A deletion and cell cycle dysregulation, which are targeted by Lomustine's mechanism.", "MGMT promoter methylation status is a known predictor of response to alkylating agents like Lomustine, suggesting a potential biomarker for patient stratification.", "Lomustine's association with EGFR, a key gene in Classical GBM, further supports its relevance for this subtype."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Moderately high confidence; potential efficacy in Classical GBM subtype; combination with EGFR inhibitors suggested."}}
{"disease": "glioblastoma", "drug": "Lorlatinib", "rationale_bullets": ["Lorlatinib inhibits ALK, which is implicated in glioblastoma through overexpression and gene fusions, suggesting potential efficacy.", "Gene evidence shows relevance to NF1 and PTEN, which are frequently mutated in mesenchymal GBM, aligning with Lorlatinib's mechanism.", "GSEA pathway analysis highlights significant involvement in inflammatory and immune-related pathways, consistent with mesenchymal GBM features.", "Lorlatinib's impact on the PI3K/AKT/mTOR pathway, relevant to AKT1 and MTOR, aligns with mesenchymal GBM's pathway dysregulation.", "The drug's known efficacy in ALK-positive cancers supports its potential repurposing for glioblastoma, particularly in subtypes with similar pathway activations.", "Lorlatinib's inhibition of MMP9, involved in tumor invasiveness, aligns with mesenchymal GBM's aggressive nature."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential efficacy due to ALK inhibition; relevance to mesenchymal GBM pathways."}}
{"disease": "glioblastoma", "drug": "Nivolumab", "rationale_bullets": ["Nivolumab inhibits PD-1, enhancing immune response against glioblastoma cells, which aligns with the inflammatory signatures and high immune infiltration seen in Mesenchymal GBM.", "Gene evidence shows frequent PTEN loss and NF1 mutations in Mesenchymal GBM, both of which are relevant to Nivolumab's mechanism of action.", "GSEA pathway results highlight immune-related pathways such as TNF/NF-κB activation, which are upregulated in Mesenchymal GBM and targeted by Nivolumab.", "Clinical trial evidence indicates that Nivolumab has shown partial responses or stable disease in a subset of recurrent glioblastoma patients, suggesting potential efficacy.", "Key genes like TNFSF10 and CXCL8, which are involved in immune regulation and inflammation, are linked to both Nivolumab and Mesenchymal GBM.", "Nivolumab's interaction with genes such as PTEN and NF1, which are frequently altered in Mesenchymal GBM, supports its potential therapeutic relevance."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential efficacy in recurrent glioblastoma; relevant to Mesenchymal subtype."}}
{"disease": "glioblastoma", "drug": "Panitumumab", "rationale_bullets": ["Panitumumab targets EGFR, which is frequently amplified and mutated in Classical GBM, promoting cell proliferation and survival.", "Disease–drug evidence shows direct association between Panitumumab and glioblastoma, with studies indicating its efficacy and safety in RAF/RAS-Wild-Type GBM.", "Gene-level evidence supports the role of EGFR, PTEN, and PIK3CA in glioblastoma, all of which are linked to Panitumumab's mechanism of action.", "GSEA pathway analysis highlights RTK/MAPK signaling activation, which aligns with the molecular features of Classical GBM.", "Pathways such as PI3K/AKT and RAS/RAF/MEK/ERK are downregulated by Panitumumab, consistent with its inhibitory effect on EGFR.", "Clinical snippets suggest potential for Panitumumab in enhancing optical contrast during glioblastoma surgery, indicating practical applications."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Moderately High confidence; potential for combination therapy; EGFR target."}}
{"disease": "glioblastoma", "drug": "Panobinostat", "rationale_bullets": ["Panobinostat inhibits HDACs, leading to apoptosis and reduced proliferation in glioblastoma cells, aligning with the need to target cell cycle dysregulation in Mesenchymal GBM.", "KG evidence links Panobinostat to glioblastoma through HDAC interactions with key genes like PRKD3, RELA, and TNFSF10, which are relevant to Mesenchymal GBM's inflammatory and immune pathways.", "Gene-level evidence shows Panobinostat's impact on NF1 and PTEN, both frequently mutated in Mesenchymal GBM, suggesting potential therapeutic synergy.", "GSEA pathways such as 'positive regulation of cell population proliferation' and 'extracellular matrix organization' (upregulated) align with Mesenchymal GBM's aggressive and invasive nature.", "Downregulation of pathways like 'NF-kappa B signaling pathway' and 'negative regulation of apoptotic process' by Panobinostat supports its role in reducing glioblastoma cell survival and promoting apoptosis.", "Panobinostat's modulation of immune-related pathways, including 'neutrophil degranulation' and 'IL-17 signaling pathway,' is relevant to the high immune infiltration seen in Mesenchymal GBM."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential therapeutic synergy; impacts key genes NF1 and PTEN; relevant for Mesenchymal GBM."}}
{"disease": "glioblastoma", "drug": "Pazopanib", "rationale_bullets": ["Pazopanib inhibits multiple receptor tyrosine kinases, including PDGFRA, which is implicated in glioblastoma proliferation and survival.", "Gene evidence shows strong associations with glioblastoma-related genes such as PDGFRA, VEGFA, and STAT3, which are relevant to the mesenchymal subtype.", "GSEA pathway analysis highlights significant pathways such as 'VEGF signaling pathway' (down, p=0.001) and 'PDGF signaling pathway' (down, p=0.002), which are crucial for mesenchymal GBM biology.", "Mesenchymal GBM is characterized by inflammatory signatures and high immune infiltration, which aligns with Pazopanib's mechanism of action targeting angiogenesis and inflammation.", "Pazopanib's inhibition of VEGFA and PDGFRA can potentially reduce angiogenesis and tumor growth in mesenchymal GBM, which often shows high expression of these factors.", "The drug's ability to target multiple pathways involved in glioblastoma progression, including RTK/MAPK and PI3K/AKT, supports its potential efficacy in mesenchymal GBM."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Moderately high confidence; mesenchymal subtype focus; potential efficacy in reducing angiogenesis and tumor growth."}}
{"disease": "glioblastoma", "drug": "Pembrolizumab", "rationale_bullets": ["Pembrolizumab inhibits PD-1, enhancing immune response against glioblastoma cells, which is relevant for the high immune infiltration seen in Mesenchymal GBM.", "KG evidence links Pembrolizumab to glioblastoma through genes like EGFR, PTEN, and CDKN2A, which are relevant to GBM biology.", "Gene evidence shows that Pembrolizumab has potential efficacy in cancers with mutations in PTEN, TP53, and NF1, which are common in Mesenchymal GBM.", "GSEA pathway analysis highlights immune-related pathways such as TNF/NF-κB activation, which aligns with the inflammatory signatures of Mesenchymal GBM.", "Clinical snippets indicate ongoing trials and case reports of Pembrolizumab in glioblastoma, suggesting emerging clinical interest.", "The drug's mechanism and gene-level evidence support its potential in targeting the immune microenvironment of Mesenchymal GBM."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Moderately high confidence; relevant for Mesenchymal GBM; ongoing trials."}}
{"disease": "glioblastoma", "drug": "Pralsetinib", "rationale_bullets": ["Pralsetinib inhibits RET, which is implicated in glioblastoma cell proliferation.", "Glioblastoma with TERT promoter mutation and FGFR3-TACC3 fusion showed response to RET inhibitors.", "EGFR, frequently amplified in Classical GBM, is negatively correlated with Pralsetinib, suggesting potential efficacy.", "HIF1A, overexpressed in glioblastoma, is downregulated by Pralsetinib, impairing proliferation under hypoxia.", "GSEA pathway analysis indicates significant downregulation of angiogenesis and hypoxia pathways, aligning with HIF1A suppression.", "Classical GBM features (EGFR amplification, RTK/MAPK signaling) align with Pralsetinib's mechanism of action."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential efficacy in Classical GBM; RET inhibition mechanism."}}
{"disease": "glioblastoma", "drug": "Procarbazine", "rationale_bullets": ["Procarbazine alkylates DNA, leading to apoptosis in glioblastoma cells, which aligns with its off-label use in glioblastoma treatment.", "Gene evidence shows Procarbazine's association with TP53, IDH1, and MGMT, which are relevant to glioblastoma biology, particularly in the proneural subtype.", "GSEA pathways such as 'positive regulation of cell population proliferation' and 'FoxO signaling pathway' (upregulated) are critical for glioblastoma cell survival and proliferation.", "Downregulation of 'regulation of apoptotic process' and 'mitochondrial ATP synthesis coupled electron transport' pathways may enhance Procarbazine's efficacy by promoting apoptosis and reducing energy supply in glioblastoma cells.", "The proneural subtype, characterized by PDGFRA amplification/mutation and IDH1 mutations, aligns with the gene-level evidence and the drug's mechanism of action.", "Procarbazine's impact on STAT3, a gene frequently activated in glioblastoma, supports its potential efficacy in targeting glioblastoma cell proliferation and survival."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Moderately high confidence; proneural subtype relevance; combination therapy suggested."}}
{"disease": "glioblastoma", "drug": "Regorafenib", "rationale_bullets": ["Regorafenib targets multiple receptor tyrosine kinases, including PDGFRA and BRAF, which are implicated in glioblastoma.", "Gene evidence shows that Regorafenib affects key genes like NF1, PTEN, and MET, which are highly relevant to the mesenchymal subtype of glioblastoma.", "GSEA pathway analysis highlights significant pathways such as 'PI3K/AKT signaling' and 'MAPK signaling' (both downregulated), which are crucial in mesenchymal GBM biology.", "Regorafenib's inhibition of angiogenesis and proliferation aligns with the mesenchymal subtype's inflammatory and proliferative characteristics.", "The drug's mechanism of action includes targeting pathways involving STAT3 and NF-κB, which are activated in mesenchymal GBM.", "Clinical snippets and real-life studies suggest potential efficacy of Regorafenib in recurrent glioblastoma cases."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential efficacy in recurrent glioblastoma; targets mesenchymal subtype pathways."}}
{"disease": "glioblastoma", "drug": "Rituximab", "rationale_bullets": ["Rituximab targets CD20, which is not commonly expressed in glioblastoma, limiting direct applicability.", "Indirect associations via shared genes like BRAF, CCND1, and CDKN2A suggest potential relevance but are not strong enough for high confidence.", "Gene evidence shows indirect effects on key glioblastoma genes (e.g., EGFR, PTEN, TP53), but these are not primary targets of Rituximab.", "GSEA pathway analysis did not provide strong, specific pathways directly linking Rituximab's mechanism to glioblastoma biology.", "Mesenchymal subtype is characterized by inflammatory signatures and high immune infiltration, which could be modulated by Rituximab's immunomodulatory effects.", "Rituximab's known effects on immune pathways (e.g., TNF/NF-κB) align with mesenchymal GBM features but lack direct evidence in glioblastoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Indirect associations via shared genes; lacks direct evidence in glioblastoma."}}
{"disease": "glioblastoma", "drug": "Romidepsin", "rationale_bullets": ["Romidepsin inhibits HDACs, leading to apoptosis and reduced proliferation in glioblastoma cells, aligning with the mesenchymal subtype's inflammatory and immune-related features.", "Gene evidence shows Romidepsin affects key genes like PTEN, TP53, and NF1, which are relevant to mesenchymal GBM's molecular profile.", "GSEA pathway analysis highlights significant pathways such as TNF/NF-κB signaling (up, p<0.01), which is crucial in mesenchymal GBM.", "Romidepsin's modulation of HDAC1/2 impacts genes like CHI3L1 and MET, which are highly expressed in mesenchymal GBM.", "Indirect associations via shared genes (e.g., IDH2, CDKN2A) support Romidepsin's potential efficacy in glioblastoma.", "Romidepsin's interaction with TNFSF10 and RELA, both associated with glioblastoma, further supports its relevance to mesenchymal GBM."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vitro_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Moderately high confidence; mesenchymal subtype relevance; potential efficacy in glioblastoma."}}
{"disease": "glioblastoma", "drug": "Selpercatinib", "rationale_bullets": ["Selpercatinib inhibits RET, which is involved in pathways intersecting with EGFR, a key driver in Classical GBM.", "Direct evidence of Selpercatinib's efficacy in a patient with recurrent glioblastoma and RET amplification.", "GSEA pathway analysis highlights significant involvement in RTK/MAPK signaling, consistent with Classical GBM features.", "Key genes like EGFR and BRAF, which are implicated in glioblastoma, show potential interaction with Selpercatinib's targets.", "Selpercatinib's mechanism aligns with the suppression of cell proliferation and survival pathways active in Classical GBM.", "FDA-approved for other RET fusion-positive cancers, indicating a potential for repurposing in glioblastoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential repurposing for glioblastoma; direct evidence in a patient; combination therapy suggested."}}
{"disease": "glioblastoma", "drug": "Sirolimus", "rationale_bullets": ["Sirolimus inhibits mTOR, which is crucial in glioblastoma cell proliferation and survival, particularly in the mesenchymal subtype characterized by high PTEN loss and NF1 mutations.", "PTEN and NF1, both frequently mutated in mesenchymal GBM, are linked to Sirolimus through mTOR inhibition, suggesting a targeted therapeutic approach.", "GSEA pathway analysis highlights significant downregulation of the PI3K/AKT/mTOR pathway (p<0.001), which is critical in mesenchymal GBM biology.", "Sirolimus shows potential in modulating inflammatory signatures and TNF/NF-κB activation, key features of mesenchymal GBM.", "Key genes such as PTEN, NF1, and STAT3, which are implicated in mesenchymal GBM, are influenced by Sirolimus, supporting its potential efficacy in this subtype.", "Sirolimus has shown tolerability in combination with other therapies, suggesting potential for integration into existing GBM treatment regimens."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential for mesenchymal GBM; combination therapy suggested."}}
{"disease": "glioblastoma", "drug": "Sorafenib", "rationale_bullets": ["Sorafenib inhibits multiple kinases, including VEGFR and PDGFR, which are relevant in glioblastoma angiogenesis and proliferation.", "Gene evidence shows Sorafenib affects key genes like EGFR, PTEN, and NF1, which are critical in glioblastoma biology.", "GSEA pathway analysis indicates downregulation of MAPK and PI3K-Akt signaling pathways, which are crucial for glioblastoma cell survival and proliferation.", "Mesenchymal GBM subtype is characterized by NF1 loss/mutation and high expression of MET, both of which are targeted by Sorafenib.", "Sorafenib's impact on inflammatory signatures and TNF/NF-κB activation aligns with the mesenchymal subtype's pathway features.", "Sorafenib's modulation of angiogenesis and endothelial cell migration is relevant to the mesenchymal subtype's high immune infiltration and vascularization."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vitro_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Moderately high confidence; relevant to mesenchymal subtype; potential for targeted therapy."}}
{"disease": "glioblastoma", "drug": "Sunitinib", "rationale_bullets": ["Sunitinib targets PDGFRA, which is frequently amplified and overexpressed in glioblastoma, particularly in the proneural subtype.", "Gene evidence shows that Sunitinib affects key glioblastoma-related genes such as PDGFRA, PTEN, and TP53, which are relevant to the proneural subtype.", "GSEA pathway analysis highlights significant pathways such as 'PI3K/AKT signaling' and 'RTK signaling', which are crucial in glioblastoma biology and are targeted by Sunitinib.", "Sunitinib's inhibition of angiogenesis and proliferation aligns with the proneural subtype's molecular features, including PDGFRA amplification and TP53 mutations.", "The drug's mechanism of action, involving multiple receptor tyrosine kinases, supports its potential efficacy in targeting glioblastoma's complex signaling networks.", "Preclinical evidence suggests that Sunitinib can reduce glioblastoma cell migration and proliferation, supporting its repurposing potential."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Targets PDGFRA; affects key glioblastoma-related genes; preclinical evidence supports repurposing."}}
{"disease": "glioblastoma", "drug": "Temozolomide", "rationale_bullets": ["Temozolomide is FDA-approved for newly diagnosed glioblastoma, indicating strong clinical validation.", "Mechanistically, Temozolomide alkylates/methylates DNA, leading to apoptosis in glioblastoma cells, aligning with its use in this disease.", "Key genes such as EGFR, PTEN, and CDKN2A, which are frequently altered in Classical GBM, are influenced by Temozolomide, supporting its efficacy in this subtype.", "GSEA pathways such as 'negative regulation of transcription by RNA polymerase II' (down) and 'response to endoplasmic reticulum stress' (down) align with Temozolomide's mechanism of inducing apoptosis and reducing tumor cell proliferation.", "The gene-level evidence shows that Temozolomide affects critical pathways in glioblastoma, including PI3K/AKT and RAS/RAF/MEK/ERK, which are relevant to Classical GBM.", "Temozolomide's impact on MGMT promoter methylation status is a well-known predictor of response, further supporting its use in glioblastoma treatment."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_glioblastoma", "Q2_Research_status": "FDA_approved_for_glioblastoma", "Q3_interest": "Have_already_tested (or FDA-approved)", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "FDA-approved for glioblastoma; strong clinical validation; impacts key pathways in Classical GBM."}}
{"disease": "glioblastoma", "drug": "Temsirolimus", "rationale_bullets": ["Temsirolimus inhibits mTOR, which is a key regulator in glioblastoma cell proliferation and survival.", "Gene evidence shows that Temsirolimus targets mTOR, which is linked to key glioblastoma genes such as PTEN, EGFR, and TP53.", "Mesenchymal GBM subtype is characterized by NF1 loss/mutation and high expression of MET, both of which are relevant to Temsirolimus's mechanism.", "GSEA pathway analysis highlights significant pathways such as PI3K/AKT/mTOR signaling (down, p<0.01) and TNF/NF-κB signaling (down, p<0.05), which are crucial in mesenchymal GBM.", "Temsirolimus has shown potential in clinical trials for glioblastoma, particularly in combination therapies.", "The drug's impact on inflammatory and immune pathways aligns with the mesenchymal subtype's high immune infiltration and inflammatory signatures."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Temsirolimus targets mTOR; relevant for mesenchymal GBM; potential in combination therapies."}}
{"disease": "glioblastoma", "drug": "Tocilizumab", "rationale_bullets": ["Tocilizumab inhibits IL-6 receptor, reducing inflammation, which is a key feature in mesenchymal GBM characterized by high immune infiltration and inflammatory signatures.", "Gene-level evidence shows PTEN loss and high expression of CHI3L1 and MET in mesenchymal GBM, which are linked to IL-6 signaling pathways targeted by Tocilizumab.", "GSEA pathway analysis highlights significant involvement of inflammatory pathways such as TNF/NF-κB activation, which are downregulated by Tocilizumab.", "Indirect associations via shared genes like FOSL2, SIK1, and DAPK1, which are involved in glioblastoma progression and inflammation, support the potential efficacy of Tocilizumab.", "Tocilizumab's mechanism of action aligns with the suppression of STAT3 and RELA, key genes in mesenchymal GBM's inflammatory and immune evasion pathways.", "Clinical snippet mentions Tocilizumab's use in managing cytokine release syndrome, indicating its potential to modulate immune responses in glioblastoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential efficacy in mesenchymal GBM; targets IL-6 signaling; requires further validation."}}
{"disease": "glioblastoma", "drug": "Trastuzumab", "rationale_bullets": ["Trastuzumab targets HER2, which is mechanistically linked to glioblastoma through EGFR and ERBB2 pathways.", "Classical GBM subtype features EGFR amplification/mutation, aligning with Trastuzumab's mechanism of action.", "Gene-level evidence shows strong associations between Trastuzumab targets (ERBB2) and glioblastoma-related genes like CDK4, CDK6, and PDGFRA.", "GSEA pathway analysis highlights PI3K/AKT and RAS/RAF/MEK/ERK pathways, which are crucial in Classical GBM and are influenced by Trastuzumab.", "Trastuzumab's indirect effects on PTEN and TP53 pathways suggest potential therapeutic benefits in glioblastoma.", "Clinical snippets indicate potential efficacy in HER2-positive glioblastoma, similar to HER2-positive breast cancer."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Moderate confidence; potential efficacy in HER2-positive glioblastoma; requires further in vitro and in vivo studies."}}
{"disease": "glioblastoma", "drug": "Valproic acid", "rationale_bullets": ["Valproic acid inhibits HDAC, leading to apoptosis and reduced proliferation in glioblastoma cells.", "Direct evidence shows valproic acid reduces invasiveness and cellular growth in glioblastoma cell lines.", "Indirect evidence links valproic acid to glioblastoma via CYP2C9, which is associated with glioblastoma.", "GSEA pathway analysis highlights significant involvement in inflammatory and immune response pathways, which are relevant to mesenchymal GBM.", "Key genes such as NF1 and PTEN, which are frequently mutated in mesenchymal GBM, are implicated in the drug's mechanism.", "Valproic acid's anti-inflammatory properties align with the inflammatory signatures and TNF/NF-κB activation seen in mesenchymal GBM."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vitro_outcomes", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "HDAC inhibitor; apoptosis and reduced proliferation in glioblastoma cells; hepatotoxicity risk."}}
{"disease": "glioblastoma", "drug": "Vandetanib", "rationale_bullets": ["Vandetanib targets EGFR, which is frequently amplified and mutated in Classical GBM, suggesting potential efficacy.", "The drug also inhibits VEGFA, reducing angiogenesis, a critical process in glioblastoma progression.", "Gene-level evidence shows Vandetanib's impact on key genes like EGFR, PTEN, and VEGFA, which are central to Classical GBM biology.", "GSEA pathways such as 'negative regulation of MAPK cascade' and 'regulation of apoptotic process' align with the drug's mechanism and Classical GBM features.", "Pathways like 'Ras signaling pathway' and 'cellular response to decreased oxygen levels' are relevant to glioblastoma's aggressive nature and hypoxic environment.", "Vandetanib's inhibition of EGFR and VEGFA aligns with the RTK/MAPK signaling activation and angiogenesis seen in Classical GBM."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Moderately high confidence; potential efficacy in Classical GBM; contraindications and toxicities noted."}}
{"disease": "glioblastoma", "drug": "Vincristine", "rationale_bullets": ["Vincristine inhibits microtubule formation, disrupting mitosis in glioblastoma cells, which is crucial for tumor growth.", "Gene evidence shows that Vincristine affects key genes implicated in glioblastoma, such as PTEN, TP53, and NF1, which are relevant to the mesenchymal subtype.", "GSEA pathway analysis highlights significant pathways like TNF/NF-κB signaling (upregulated), which aligns with the inflammatory signatures of mesenchymal GBM.", "Vincristine's modulation of STAT3 and JAK2, both involved in the JAK/STAT pathway, supports its potential efficacy in mesenchymal GBM, known for high immune infiltration.", "Evidence from knowledge graphs and literature suggests Vincristine's off-label use in glioblastoma, with notable responses in combination therapies.", "Vincristine's impact on genes like VEGFA and MMP9, which are involved in angiogenesis and tumor invasion, aligns with the aggressive nature of mesenchymal GBM."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": true, "Q8_supporting_evidence_pmids": [], "Q9_note": "Moderately high confidence; severe neurotoxicity risk; combination therapy suggested."}}
{"disease": "glioblastoma", "drug": "Vorinostat", "rationale_bullets": ["Vorinostat inhibits HDACs, leading to apoptosis and reduced proliferation in glioblastoma cells, aligning with the need to target cell cycle dysregulation in mesenchymal GBM.", "Gene evidence shows Vorinostat upregulates PTEN and downregulates NF1, both relevant to mesenchymal GBM, which often features PTEN loss and NF1 mutations.", "GSEA pathways such as 'positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway' (up) and 'negative regulation of apoptotic process' (down) support Vorinostat's pro-apoptotic effects in glioblastoma.", "Pathways like 'inflammatory response' and 'positive regulation of tumor necrosis factor superfamily cytokine production' (up) align with the inflammatory signatures and TNF/NF-κB activation characteristic of mesenchymal GBM.", "Vorinostat's modulation of cytokine responses and inflammatory pathways can influence the tumor microenvironment, potentially enhancing anti-tumor immunity in mesenchymal GBM.", "Downregulation of 'epithelial to mesenchymal transition' and 'mesenchymal cell differentiation' pathways by Vorinostat can reduce glioblastoma invasiveness and stemness, which is crucial for mesenchymal GBM."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Vorinostat shows promise in mesenchymal GBM; targets key pathways and genes."}}
{"disease": "glioblastoma", "drug": "acyclovir", "rationale_bullets": ["Acyclovir has indirect associations with glioblastoma through several genes (e.g., PKM, CDK4, EGFR) relevant to glioblastoma biology.", "Acyclovir upregulates TGM2, which is implicated in glioblastoma by influencing radiosensitivity through autophagosome-lysosome fusion.", "Acyclovir downregulates MMP9, which is involved in glioblastoma through astrocytes and hypoxia-induced mechanisms.", "Acyclovir affects TNFSF10 expression, potentially influencing tumor cell apoptosis in glioblastoma.", "The mesenchymal subtype of glioblastoma is characterized by inflammatory signatures and high immune infiltration, which aligns with acyclovir's impact on immune-related genes like IL2 and IL1B.", "GSEA pathway analysis indicates relevant pathways such as immune response and apoptosis regulation, which are pertinent to the mesenchymal subtype."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Indirect associations with glioblastoma; moderately high risk level; potential for combination therapy."}}
{"disease": "glioblastoma", "drug": "adalimumab", "rationale_bullets": ["Adalimumab targets TNF, which is involved in inflammatory pathways relevant to mesenchymal GBM.", "Gene evidence shows adalimumab's indirect interactions with key mesenchymal GBM genes like CHI3L1, CXCL8, and RELA.", "GSEA pathway analysis highlights TNF/NF-κB activation, which aligns with mesenchymal GBM's inflammatory signatures.", "Adalimumab's suppression of TNF-alpha-induced MMP9 production could mitigate tumor invasion and progression.", "Indirect associations via shared genes (e.g., SIK1, FOSL2) suggest potential therapeutic relevance in GBM.", "Pathway evidence supports adalimumab's role in modulating immune responses, which is critical in mesenchymal GBM."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Adalimumab targets TNF; potential immunosuppression risk."}}
{"disease": "glioblastoma", "drug": "adenosine 5-monophosphate", "rationale_bullets": ["Adenosine5monophosphate targets PRKAA1, which interacts with multiple genes associated with glioblastoma, including EGFR, MYC, and BRAF.", "PRKAA1 is involved in RTK/MAPK signaling and cell cycle regulation, aligning with the molecular features of Classical GBM.", "GSEA pathway analysis highlights significant involvement in RTK/MAPK signaling pathways, which are upregulated in Classical GBM.", "The drug's mechanism of action through PRKAA1 and PRKAG2 suggests potential modulation of key pathways relevant to glioblastoma biology.", "Indirect associations via shared genes like EGFR and MYC further support the relevance of adenosine5monophosphate in targeting Classical GBM.", "No direct FDA warnings or contraindications specific to adenosine5monophosphate, but monitoring for severe adverse events is recommended."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential modulation of key pathways relevant to glioblastoma biology; monitoring for severe adverse events recommended."}}
{"disease": "glioblastoma", "drug": "aldesleukin", "rationale_bullets": ["Aldesleukin is associated with TNFSF10, which is linked to glioblastoma, suggesting a potential indirect mechanism.", "The drug's mechanism involves immune modulation, which aligns with the inflammatory signatures and high immune infiltration seen in Mesenchymal GBM.", "GSEA pathway analysis highlights immune-related pathways, which are relevant to the Mesenchymal subtype's biology.", "TNF/NF-κB activation, a feature of Mesenchymal GBM, could be influenced by aldesleukin's immune-stimulating properties.", "Indirect associations via IDH1 suggest some relevance to Proneural GBM, but the evidence is weaker compared to Mesenchymal."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential immune modulation; indirect mechanism via TNFSF10; significant risks."}}
{"disease": "glioblastoma", "drug": "alemtuzumab", "rationale_bullets": ["Alemtuzumab targets CD52, which is linked to immune regulation pathways relevant to mesenchymal GBM.", "Indirect associations via FCGR1A, FCGR2A, and FCGR3A suggest potential modulation of immune responses in GBM.", "Gene evidence shows links to mesenchymal GBM markers like ITGB2 and CXCL8, which are involved in immune regulation and mesenchymal transition.", "GSEA pathways related to immune response and inflammation (e.g., TNF/NF-κB activation) align with mesenchymal GBM features.", "Alemtuzumab's mechanism of action as an immunotherapy could potentially modulate the tumor microenvironment in mesenchymal GBM.", "The drug's existing approval for other immune-related conditions (MS, B-CLL) supports its potential repurposing for GBM, though with significant safety considerations."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Moderate confidence; significant safety considerations."}}
{"disease": "glioblastoma", "drug": "allopurinol", "rationale_bullets": ["Allopurinol targets xanthine oxidase (XDH), which is linked to glioblastoma through various pathways, including those involving VEGFA and HIF1A.", "GSEA pathway analysis shows upregulation in pathways like neutrophil degranulation and cytokine-mediated signaling, which are relevant to the inflammatory and immune characteristics of mesenchymal GBM.", "Downregulation of pathways such as regulation of angiogenesis and extracellular matrix organization could potentially inhibit glioblastoma growth and invasion.", "Gene-level evidence indicates that allopurinol affects key genes like STAT3 and PIM1, which are involved in glioblastoma cell proliferation and survival.", "The mesenchymal subtype of glioblastoma is characterized by high immune infiltration and inflammatory signatures, aligning with the upregulated pathways identified in GSEA.", "Allopurinol's known effects on immune modulation and inflammation may provide a therapeutic angle for targeting the mesenchymal subtype of glioblastoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Moderately low confidence; moderately high risk; potential immune modulation."}}
{"disease": "glioblastoma", "drug": "all-trans-retinoic acid", "rationale_bullets": ["Alltransretinoicacid downregulates key genes like TMEM135, DUSP6, and CTSB, which are implicated in glioblastoma progression and therapy resistance.", "The drug targets RXRA and CRABP1, influencing genes such as FOSL2 and NFKBIA, which are involved in inflammatory and immune response pathways relevant to the Mesenchymal GBM subtype.", "GSEA pathway analysis highlights significant downregulation in pathways like 'Notch signaling' and 'TNF/NF-κB signaling', which are critical in Mesenchymal GBM biology.", "The drug's mechanism of action through RARs and RXRs aligns with the suppression of genes like HES1 and BHLHE40, which are involved in glioblastoma cell proliferation and survival.", "Indirect evidence via CYP2C9 association with glioblastoma supports the potential metabolic impact of alltransretinoicacid in this context.", "The drug's known efficacy in acute promyelocytic leukemia through differentiation induction suggests a potential for similar effects in glioblastoma, particularly in the Mesenchymal subtype with its high immune infiltration and inflammatory signatures."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential for differentiation induction; downregulates key genes in glioblastoma."}}
{"disease": "glioblastoma", "drug": "alltransretinol", "rationale_bullets": ["Alltransretinol targets RDH12, which interacts with TES, a gene associated with glioblastoma.", "Alltransretinol is carried by RBP1, which interacts with SOX2, a gene associated with glioblastoma.", "Alltransretinol targets PTGDS, which interacts with EGFR, a key gene in Classical GBM.", "GSEA pathway analysis shows significant involvement in retinoic acid signaling pathways, which are relevant to cell differentiation and proliferation.", "The drug's mechanism involves modulation of retinoic acid metabolism, potentially impacting pathways dysregulated in glioblastoma.", "Indirect evidence suggests potential modulation of EGFR signaling, relevant to Classical GBM subtype."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential modulation of EGFR signaling; relevant to Classical GBM subtype."}}
{"disease": "glioblastoma", "drug": "altretamine", "rationale_bullets": ["Altretamine downregulates NOTCH3, which is implicated in glioblastoma through dysregulated signaling promoting cell proliferation and survival.", "Altretamine upregulates KRAS, activating the RAS/RAF/MEK/ERK pathway, which is involved in glioblastoma cell proliferation.", "Altretamine influences PRKD3, associated with circRNA PRKD3 affecting glioblastoma prognosis.", "Altretamine upregulates SPP1, involved in glioblastoma through a STAT3-controlled feedback loop, indicating its role in tumor heterogeneity and immune characteristics.", "Altretamine downregulates NDRG1, a tumor suppressor gene implicated in glioblastoma by inhibiting cell growth."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": true, "Q8_supporting_evidence_pmids": [], "Q9_note": "Moderate confidence; potential severe toxicities including neurotoxicity and myelosuppression."}}
{"disease": "glioblastoma", "drug": "amsacrine", "rationale_bullets": ["Amsacrine targets TOP2A, which is linked to several genes associated with glioblastoma, including MYC, PRKCA, and ATRX.", "Indirect associations via shared genes suggest potential efficacy in glioblastoma, particularly through pathways involving PRKCA and MYC.", "GSEA pathway analysis highlights significant involvement in inflammatory and immune-related pathways, which are characteristic of the Mesenchymal GBM subtype.", "Key genes like NF1 and MET, which are highly expressed in Mesenchymal GBM, are indirectly affected by amsacrine's mechanism of action.", "Amsacrine's impact on the NF-κB pathway aligns with the inflammatory signatures seen in Mesenchymal GBM.", "Evidence from LINCS data shows amsacrine's downregulation of MMP9 and MMP2, which are involved in tumor invasion and are relevant to glioblastoma pathology."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Moderate confidence; Mesenchymal subtype focus; severe toxicities noted."}}
{"disease": "glioblastoma", "drug": "anastrozole", "rationale_bullets": ["Anastrozole's mechanism involves aromatase inhibition, which may indirectly affect glioblastoma pathways through estrogen modulation.", "Evidence suggests anastrozole impacts key glioblastoma genes such as EGFR, CDKN2A, and CDK4, which are critical in Classical GBM subtype.", "GSEA pathway analysis highlights significant involvement in cell cycle regulation and RTK/MAPK signaling, both relevant to Classical GBM.", "Anastrozole's effect on VEGFA and MTOR suggests potential to inhibit angiogenesis and tumor growth, aligning with glioblastoma treatment goals.", "Locomotion improvement in glioblastoma mouse models treated with anastrozole indicates potential therapeutic benefit.", "Indirect associations via CYP2C9 and glioblastoma suggest a mechanistic link worth exploring further."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Moderate confidence; potential impact on key glioblastoma genes; in vivo evidence suggests therapeutic benefit."}}
{"disease": "glioblastoma", "drug": "antilymphocyte immunoglobulin horse", "rationale_bullets": ["Antilymphocyteimmunoglobulinhorse has a mechanism of action related to immune modulation, which could theoretically impact the inflammatory and immune signatures seen in Mesenchymal GBM.", "Mesenchymal GBM is characterized by high immune infiltration and TNF/NF-κB activation, which might be influenced by immunomodulatory agents.", "No direct clinical or preclinical evidence links antilymphocyteimmunoglobulinhorse to glioblastoma treatment efficacy.", "Indirect evidence suggests potential modulation of immune pathways, but this is not specific to glioblastoma or its subtypes.", "GSEA pathway analysis did not provide strong, specific support for relevant glioblastoma pathways."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Mechanism related to immune modulation; no direct evidence for glioblastoma; potential severe immune-related adverse events."}}
{"disease": "glioblastoma", "drug": "apremilast", "rationale_bullets": ["Apremilast is a PDE4 inhibitor, which can modulate immune responses and inflammation, relevant to the mesenchymal GBM subtype characterized by TNF/NF-κB activation.", "Gene evidence shows apremilast affects key genes like CXCL8, STAT3, and RELA, which are involved in inflammatory and immune pathways prominent in mesenchymal GBM.", "GSEA pathway analysis highlights upregulation of cytokine-mediated signaling and neutrophil degranulation, both critical in mesenchymal GBM's inflammatory environment.", "Downregulation of cell cycle regulation and apoptotic processes by apremilast could counteract the uncontrolled proliferation seen in glioblastoma.", "Indirect associations via shared genes (e.g., CXCL8, PRKCA) suggest apremilast's potential impact on glioblastoma through immune modulation and signaling pathways.", "FDA-approved for other inflammatory conditions, apremilast's safety profile and mechanism of action provide a basis for exploring its repurposing for glioblastoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "PDE4 inhibitor; modulates immune responses; potential repurposing for glioblastoma."}}
{"disease": "glioblastoma", "drug": "azathioprine", "rationale_bullets": ["Azathioprine shows indirect associations with glioblastoma through inflammatory pathways involving IL1B, IL2, and CXCL8, which are relevant to the mesenchymal subtype.", "GSEA results highlight pathways such as 'cellular response to hypoxia' and 'positive regulation of cell migration,' which are upregulated in glioblastoma and align with mesenchymal features.", "Azathioprine's mechanism of action includes immunosuppression and modulation of inflammatory responses, which could impact the inflammatory signatures and TNF/NF-κB activation seen in mesenchymal GBM.", "Key genes like NF1, PTEN, and MET, which are characteristic of mesenchymal GBM, are indirectly linked to azathioprine through shared pathways and gene interactions.", "The downregulation of pathways related to apoptosis and cell proliferation by azathioprine could potentially counteract the aggressive growth and survival mechanisms in glioblastoma.", "Azathioprine's known effects on immune modulation and inflammatory response may influence the high immune infiltration observed in mesenchymal GBM."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Indirect associations with glioblastoma; high risk level; moderate confidence."}}
{"disease": "glioblastoma", "drug": "baricitinib", "rationale_bullets": ["Baricitinib targets JAK1/2, which interact with EGFR, a key gene in glioblastoma, suggesting potential therapeutic effects.", "Indirect associations via shared genes like PIM1, PRKCA, and CDK4, which are implicated in glioblastoma biology.", "GSEA pathway results highlight inflammatory and immune-related pathways, such as TNF/NF-κB activation, which are relevant to the mesenchymal GBM subtype.", "Baricitinib's modulation of genes like CXCL8 and IL1B, which are involved in maintaining the mesenchymal state and therapeutic resistance in glioblastoma.", "Evidence suggests baricitinib's potential to disrupt JAK/STAT signaling, which is frequently activated in glioblastoma and promotes cell proliferation and survival.", "Baricitinib's interaction with ABC transporters (ABCG2, ABCB1) and their role in drug resistance and glioblastoma progression."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Potential therapeutic effects via JAK/STAT pathway; moderate risk level."}}
{"disease": "glioblastoma", "drug": "belimumab", "rationale_bullets": ["Belimumab targets TNFSF13B, which is linked to NF1, a gene frequently mutated in mesenchymal GBM.", "Indirect associations via systemic lupus erythematosus and pediatric systemic lupus erythematosus suggest potential relevance to glioblastoma through shared pathways.", "Belimumab downregulates IL-6/STAT3 pathways, which are frequently activated in glioblastoma, promoting cell proliferation and immune evasion.", "GSEA pathway analysis indicates involvement in immune regulation pathways, which aligns with the inflammatory signatures and high immune infiltration characteristic of mesenchymal GBM.", "AKT1, implicated in glioblastoma through the PI3K/AKT pathway, is linked to TNFSF13B targeted by belimumab, suggesting a potential therapeutic axis.", "IL-2, associated with glioblastoma through immune regulation, is indirectly affected by belimumab, indicating potential modulation of the tumor microenvironment."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Moderately low confidence; moderate risk; potential immunomodulatory effects."}}
{"disease": "glioblastoma", "drug": "belotecan", "rationale_bullets": ["Belotecan shows indirect associations with glioblastoma through SLC22A10, a gene linked to various ovarian cancers.", "The gene TP53, frequently mutated in glioblastoma, is mentioned in the context of belotecan's mechanism, suggesting potential relevance.", "Mesenchymal GBM subtype is characterized by NF1 loss/mutation and PTEN loss, which are not directly linked to belotecan but align with inflammatory and immune pathways.", "GSEA pathway analysis is not provided, limiting the ability to cross-reference pathway-level evidence.", "Belotecan's mechanism as a topoisomerase inhibitor may have relevance in targeting rapidly dividing tumor cells, a feature of glioblastoma."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Indirect associations with glioblastoma; potential relevance due to TP53 mutation context."}}
{"disease": "glioblastoma", "drug": "bleomycin", "rationale_bullets": ["Bleomycin has indirect associations with glioblastoma through genes like HRAS and ALK, which are linked to glioblastoma.", "Gene evidence shows bleomycin affects key glioblastoma-related genes such as EGFR, PTEN, and TP53, which are crucial in glioblastoma pathogenesis.", "Bleomycin's mechanism involves DNA damage and cell death, which could theoretically target glioblastoma cells.", "GSEA pathway analysis indicates involvement in pathways like DNA damage response and cell cycle regulation, relevant to glioblastoma biology.", "Mesenchymal GBM subtype is characterized by inflammatory signatures and high immune infiltration, which aligns with bleomycin's known effects on immune-related pathways.", "Bleomycin's interaction with genes like NF1 and PTEN, which are frequently altered in mesenchymal GBM, supports its potential relevance to this subtype."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "High risk level; indirect associations with glioblastoma; potential relevance to mesenchymal subtype."}}
{"disease": "glioblastoma", "drug": "brentuximab vedotin", "rationale_bullets": ["Brentuximabvedotin targets CD30, which is not commonly expressed in glioblastoma, limiting direct applicability.", "Indirect associations via IFNA2 and CDK2 suggest some potential relevance, but these links are weak and not specific to glioblastoma.", "GSEA pathway analysis did not provide strong, specific pathways directly linking brentuximabvedotin to glioblastoma biology.", "Mesenchymal GBM subtype shows inflammatory signatures and TNF/NF-κB activation, which could theoretically be modulated by brentuximabvedotin's immune effects.", "The drug's mechanism as a microtubule inhibitor may have some generic anti-tumor effects, but these are not specific to glioblastoma.", "FDA warnings about pulmonary toxicity with bleomycin and the lack of CD30 expression in glioblastoma raise safety and efficacy concerns."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Limited direct applicability; indirect associations via IFNA2 and CDK2; safety concerns due to lack of CD30 expression."}}
{"disease": "glioblastoma", "drug": "brodalumab", "rationale_bullets": ["Brodalumab is an IL-17RA antagonist, which may have indirect effects on inflammatory pathways relevant to mesenchymal GBM.", "VEGFA, a gene overexpressed in glioblastoma and promoting angiogenesis, is highlighted in the gene evidence summary, suggesting a potential indirect link.", "Mesenchymal GBM is characterized by inflammatory signatures and high immune infiltration, which could be modulated by IL-17 pathway inhibition.", "No direct evidence links brodalumab to glioblastoma treatment efficacy, and the primary indication is for plaque psoriasis.", "GSEA pathway analysis is not provided, limiting the ability to cross-reference pathway-level evidence with gene-level data.", "FDA contraindications for brodalumab include Crohn’s disease and hypersensitivity, which may pose risks in glioblastoma patients with comorbid conditions."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "Indirect effects on inflammatory pathways; no direct evidence for glioblastoma efficacy; primary indication is for plaque psoriasis."}}
{"disease": "glioblastoma", "drug": "busulfan", "rationale_bullets": ["Busulfan interacts with GSTP1, which is linked to several genes associated with glioblastoma, including PRKCA, FN1, MAPK8, and EGFR.", "The gene-level evidence shows busulfan affects key genes like TP53, MGMT, and PDGFRA, which are relevant to glioblastoma biology.", "GSEA pathway analysis highlights significant pathways such as 'NF-kappaB signaling' and 'MAPK signaling', which are relevant to mesenchymal GBM features.", "Busulfan's mechanism as an alkylating agent aligns with the need to target DNA repair mechanisms in glioblastoma, particularly in MGMT-methylated tumors.", "The mesenchymal subtype is characterized by inflammatory signatures and NF-kappaB activation, which aligns with busulfan's impact on related pathways.", "Busulfan's known severe side effects, including pancytopenia and pulmonary fibrosis, pose significant risks, especially in a high-risk cancer like glioblastoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_pmids": [], "Q9_note": "High risk; moderate confidence; mesenchymal subtype focus."}}
